Krauer B, Krauer F
Clin Pharmacokinet. 1977 May-Jun;2(3):167-81. doi: 10.2165/00003088-197702030-00002.
Any drug given to a pregnant woman must be considered as possibly harmful in the fetus, since all drugs administered to the mother cross the placental membrane, although at different rates. Important physiological changes occur in pregnancy, which may influence the kinetics of drugs. Differences in gastrointestinal function are likely to alter drug absorption rates in the stomach or gut. Ventilatory alterations modify pulmonary drug absorption or elimination. Important changes in haemodynamics and alterations in body water compartments influence drug distribution and elimination. Renal drug elimination is generally enhanced, whereas hepatic drug elimination may be modified in different ways. Computerised pharmacokinetic models representing the compartmental aspects of the fetal-maternal unit and fetal-maternal drug interrelationships may be used to predict kinetic consequences of fetal drug exposure. Such information may be a useful guide for the clinical use of drugs during pregnancy, particularly for treatment of fetal disease.
给孕妇使用的任何药物都必须被视为可能对胎儿有害,因为给母亲使用的所有药物都会穿过胎盘膜,尽管速率不同。孕期会发生重要的生理变化,这可能会影响药物的动力学。胃肠功能的差异可能会改变药物在胃或肠道的吸收速率。通气改变会影响肺部药物的吸收或消除。血流动力学的重要变化和体内水分分布的改变会影响药物的分布和消除。肾脏药物消除通常会增强,而肝脏药物消除可能会以不同方式发生改变。代表胎儿-母体单元的房室方面和胎儿-母体药物相互关系的计算机化药代动力学模型可用于预测胎儿接触药物的动力学后果。这些信息可能是孕期药物临床使用的有用指南,尤其是用于治疗胎儿疾病。